Information
Unichem Pharmaceuticals USA Inc. Recalls Doxazosin Tablets
This is a Class III recall. This product is unlikely to cause adverse health reactions but violates FDA regulations.
Source: FDA
InfoRecall #D-0306-2026Drug / Pharmaceutical
Unichem Pharmaceuticals USA Inc. Recalls Doxazosin Tablets
Unichem Pharmaceuticals USA Inc. · Class III — Regulatory
Product Description
Doxazosin Tablets, USP, 4 mg, 1000 tablets per bottle, Rx only, distributed by Unichem Pharmaceuticals (USA), Inc., 1 Tower Center Boulevard, Suite 2200, East Brunswick, NJ 08816 USA, manufactured by Unichem Laboratories Limited, Plot Number 15 to 18, Pilerne Industrial Estate, Pilerne, Bardez, Goa (India) 403511, NDC 29300-353-10.
Reason for Recall
Tablets/Capsules Imprinted with Wrong ID
FDA Classification
Class III — Regulatory
A situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Distribution
Nationwide
Remedy
Consumers should stop using this product. Contact the recalling firm for further instructions regarding this product.
411 Press Analysis
A regulatory compliance recall has been issued for a pharmaceutical product from Unichem Pharmaceuticals USA Inc. The FDA classified this as Class III on January 21, 2026 affecting 60,000 tablets. Tablets/Capsules Imprinted with Wrong ID. It was distributed nationwide. While this classification indicates a low probability of adverse health effects, consumers should be aware of the recall and follow any instructions from the manufacturer.
Sources: FDA openFDA Enforcement Database
This recall appears in: Other Injury Hazards.